CONJUCHEM REVEALS FINDINGS OF PATIENT DEATH INVESTIGATION

ConjuChem Biotechnologies has posted the findings of its investigation into the recent death of a patient in its Phase II trial of DAC:GRF in HIV lipodystrophy, an event that caused the company to halt the trial and, subsequently, lose half the value of its stock.
Pharmaceutical Business Review